Error message

Please note: Our system will be undergoing maintenance on Thursday, May 25th , 8:30 AM ET, through Monday, June 5th , 12:30 PM ET, During this time, SFB login and transaction-related services will be down. Should you have any urgent issues, please reach out directly to info@biomaterials.org. Thank you!
  • Print

New Classification System Developed for Regenerative Cell-Based Therapies

New Classification System Developed for Regenerative Cell-Based Therapies

For Immediate Release on February 20, 2020

FARMINGTON – Doctors at UConn Health have developed the first classification system for regenerative cell-based therapies designed to stratify therapies based on scientific evidence and potential for harm. Today, there are concerns regarding the clinical safety and efficacy of cell-based therapies throughout the scientific community and within public discourse. The unregulated U.S. stem cell market has been widely reported as it offers potentially harmful therapies to patients without FDA approval. Currently, there are no regenerative cell-based therapies approved by the FDA, although high demand for such treatments is ongoing.

In light of these concerns, the current climate has generated demand for a systematic method to assess potential therapies. Dr. Cato T. Laurencin, CEO of The Connecticut Convergence Institute for Translation in Regenerative Engineering at UConn Health, has created a new classification system for cell-based therapies.

To learn more about the new classification system, view the newly published article here. 

To view the full press release, click here.